Whitehawk Therapeutics

Company snapshot

Whitehawk Therapeutics is an ADC-focused oncology company applying advanced technologies to established tumor biology to efficiently deliver improved cancer treatments. Building on the momentum of drug conjugate technologies, Whitehawk’s three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to

• 1 active pipeline program(s) linked via ClinicalTrials.gov.
• 1 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Whitehawk Therapeutics. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Whitehawk Therapeutics.

1. May 23, 2026 Clinical update

   HWK-007 — Phase 1

View all clinical trial activity →

• What is Whitehawk Therapeutics?

  Whitehawk Therapeutics is a pharma organization headquartered in Morristown, USA. It trades on NYSE under ticker WHWK. Primary therapeutic focus areas include Endometrial Cancer. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity

• Is Whitehawk Therapeutics publicly traded?

  Yes. Whitehawk Therapeutics is listed with ticker WHWK on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Whitehawk Therapeutics develop or market?

  No drug profiles are currently linked to Whitehawk Therapeutics. Pipeline programs may still list investigational assets.

• What are the latest developments for Whitehawk Therapeutics?

  In the last 12 months our linked public records show 1 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Whitehawk Therapeutics focus on?

  Whitehawk Therapeutics focuses on Endometrial Cancer based on our analysis of their pipeline programs and drug development activities.